Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Trastuzumab + Trifluridine-tipiracil hydrochloride + Tucatinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Trastuzumab||Herceptin||Anti HER2||HER2 (ERBB2) Antibody 57||Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov).|
|Trifluridine-tipiracil hydrochloride||Lonsurf||TAS-102|TAS102|TAS 102|S 95005|S95005|S-95005||Lonsurf (trifluridine/tipiracil hydrochloride) is an oral combination comprised of TFT and a thymidine phosphorylase inhibitor, which can result in DNA fragmentation thereby preventing angiogenesis and tumor growth and is FDA approved for use in patients with colorectal cancer, gastric or gastroesophageal junction adenocarcinoma (FDA.gov).|
|Tucatinib||Tukysa||ONT-380|ARRY-380|irbinitinib||HER2 Inhibitor 32||Tukysa (tucatinib) selectivity inhibits ERBB2 (HER2), resulting in decreased proliferation and increased apoptosis in ERBB2 (HER2) expressing tumor cells (PMID: 28053022). Tukysa (tucatinib) in combination with Herceptin (trastuzumab) and Xeloda (capecitabine) is FDA approved for use in patients with advanced unresectable or metastatic ERBB2 (HER2)-positive breast cancer, including patients with brain metastasis, who have received prior anti-HER2 therapies (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05356897||Phase II||Trastuzumab + Trifluridine-tipiracil hydrochloride + Tucatinib||Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study||Not yet recruiting||USA||0|